ADCT
HealthcareADC Therapeutics S.A. · Biotechnology · $430M
What is ADC Therapeutics S.A.?
ADC Therapeutics is a commercial-stage biotechnology company focused on antibody drug conjugates — a targeted approach to treating blood cancers and solid tumors. Headquartered in Epalinges, Switzerland, the company is advancing a pipeline built around precision oncology.
The company engineers antibody drug conjugates (ADCs) — molecules that deliver cancer-killing agents directly to tumor cells while sparing healthy tissue. Its lead commercial product, ZYNLONTA, targets relapsed or refractory diffuse large B-cell lymphoma across multiple clinical stages. Beyond ZYNLONTA, the pipeline includes camidanlumab tesirine for Hodgkin lymphoma and several early-stage candidates targeting both blood cancers and solid tumors. Revenue is supported by product sales and collaboration agreements with established pharmaceutical partners.
ADC Therapeutics was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
- ZYNLONTA — approved ADC for relapsed or refractory DLBCL
- Camidanlumab tesirine — ADC in Phase II for Hodgkin lymphoma
- ADCT-602 — Phase I candidate for acute lymphoblastic leukemia
- ADCT-601 and ADCT-901 — early-stage solid tumor programs
- Collaboration agreements with Genmab, Mitsubishi Tanabe, and others
Is ADCT a Good Stock to Buy?
UQS Score rates ADCT as Below Average overall, reflecting a mixed profile typical of early commercial-stage biotechs.
The Risk pillar stands out as a relative bright spot, suggesting the company's financial structure carries less near-term distress signal than many peers at this stage. The Growth pillar also rates Good, consistent with a company that has a commercial product on the market and an expanding clinical pipeline.
Quality rates Weak, reflecting the financial realities of a company still scaling its commercial operations. Valuation rates Elevated, meaning the current market price may already reflect optimistic expectations.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ADCT pay dividends?
No — ADC Therapeutics S.A. does not currently pay a dividend.
ADCT does not pay a dividend, which is standard for commercial-stage biotechs. Capital is directed toward clinical development, commercialization of ZYNLONTA, and pipeline expansion. Investors in this name are typically seeking growth from drug approvals and label expansions rather than income distributions.
When does ADCT report earnings?
ADC Therapeutics reports earnings on a quarterly cadence, typical for US-listed equities.
Results in recent periods have reflected the dual reality of a company with a commercial product generating revenue while continuing to invest heavily in clinical trials. Operating expenses tied to R&D and commercialization remain a defining feature of the income statement at this stage.
For the most recent quarter's results, visit ADC Therapeutics' investor relations page directly.
ADCT Price History
-81.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in ADC Therapeutics S.A.?
Based on ADC Therapeutics S.A.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ADCT Long-term Outlook
The fundamental outlook for ADCT is shaped by two competing forces: a Good Growth profile driven by ZYNLONTA's commercial trajectory and a deep pipeline, offset by a Weak Quality profile that reflects the cost burden of operating as a commercial-stage biotech. The Elevated Valuation pillar suggests the market is pricing in meaningful pipeline success, leaving limited margin for setbacks. The Strong Risk pillar provides some reassurance that near-term financial stability is not the primary concern.
Growth drivers
- Expansion of ZYNLONTA into additional lymphoma indications and combination regimens
- Advancement of camidanlumab tesirine and early-stage pipeline candidates toward later-stage trials
- Revenue contributions from collaboration and licensing agreements with global pharma partners
Key risks
- Clinical trial failures or delays could significantly reset growth expectations
- Elevated valuation leaves little room for execution shortfalls
- Ongoing R&D and commercialization spending pressures near-term profitability
ADCT vs Peers
ADCT operates in a competitive small-cap biotech space alongside other clinical and commercial-stage companies developing novel therapeutics.
4D Molecular Therapeutics focuses on gene therapy using engineered viral vectors, a distinct modality from ADC Therapeutics' antibody drug conjugate approach.
Entrada Therapeutics develops intracellular therapeutics using its FETCH platform, targeting diseases through a different delivery mechanism than ADCs.
Relmada Therapeutics is focused on central nervous system disorders rather than oncology, making it a sector peer by market profile rather than therapeutic area.
Frequently Asked Questions
What does ADC Therapeutics do?
ADC Therapeutics develops antibody drug conjugates — targeted cancer therapies that attach a toxic payload to an antibody designed to seek out tumor cells. Its lead commercial product, ZYNLONTA, is approved for certain types of relapsed or refractory large B-cell lymphoma. The company also has a pipeline of candidates in various stages of clinical development for blood cancers and solid tumors.
Does ADCT pay dividends?
ADCT does not currently pay a dividend. As a commercial-stage biotech, the company reinvests available capital into clinical development and the commercialization of its existing products. Investors in ADCT are generally focused on pipeline progress rather than income.
When does ADCT report earnings?
ADC Therapeutics reports financial results on a quarterly basis, consistent with US-listed public companies. For exact dates and the most recent earnings releases, check the investor relations section of the company's official website.
Is ADCT a good stock to buy?
UQS Score rates ADCT as Below Average overall. The Growth and Risk pillars show relative strength, but Quality rates Weak and Valuation rates Elevated. Whether ADCT fits a portfolio depends on individual risk tolerance and investment goals. The full pillar breakdown is available to UQS Pro members.
Is ADCT overvalued?
The UQS Valuation pillar for ADCT rates Elevated, suggesting the current market price reflects optimistic assumptions about pipeline success. This is not uncommon for commercial-stage biotechs with approved products and active clinical programs, but it does mean there is limited buffer if results disappoint.
How does ADCT compare to its competitors?
ADCT's focus on antibody drug conjugates for oncology distinguishes it from peers like 4D Molecular Therapeutics, which uses gene therapy, and Relmada Therapeutics, which targets CNS disorders. Within the ADC space specifically, ADCT benefits from having a commercially approved product, which separates it from purely pre-commercial peers.
What is ADCT's market cap bracket?
ADCT is classified as a small-cap stock. This places it in a segment of the market that can offer higher growth potential but also carries greater volatility and liquidity risk compared to large- or mega-cap companies.
Who founded ADC Therapeutics?
ADC Therapeutics was incorporated in 2011. Founding and leadership history is publicly available through the company's official disclosures and investor relations materials for those seeking detailed background.
Is ADCT a long-term quality investment?
As a long-term quality indicator, UQS rates ADCT as Below Average. The Good Growth profile and Strong Risk pillar offer some foundation, but the Weak Quality pillar and Elevated Valuation are meaningful considerations for investors with a long time horizon. Pro members can view the complete analysis to assess fit.
What is the main competitive advantage of ADC Therapeutics?
ADC Therapeutics' primary differentiation lies in its proprietary pyrrolobenzodiazepine-based ADC technology and its status as a commercial-stage company with an approved product. Having ZYNLONTA on the market provides both revenue and clinical credibility that purely pre-commercial peers lack.
What sector does ADCT belong to?
ADCT belongs to the Healthcare sector, specifically within the biotechnology industry. It focuses on oncology — developing targeted therapies for patients with blood cancers and solid tumors who have limited treatment options.
Is ADCT a growth stock or value stock?
Based on UQS pillar labels, ADCT leans toward growth — the Growth pillar rates Good, reflecting commercial momentum and an active pipeline. However, the Elevated Valuation pillar means investors are already paying a premium for that growth potential, which is a characteristic of growth-oriented names rather than value plays.
Unlock Full ADCT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access detailed financial metrics and trend data
- ✓Compare ADCT against sector peers side by side
- ✓See the complete Quality and Valuation breakdown
- ✓Track pipeline-stage risk signals in one dashboard
- ✓Get the full analyst-grade view for Pro members
Pro Analysis
ADCT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | 42.9 | 26.3 | 42.0 | 67.2 | 82.4 | 0.0 | +1.6 |
| May 10, 2026 | 41.3 | 20.0 | 42.0 | 67.2 | 82.4 | 0.0 | -1.6 |
| Apr 2, 2026 | 42.9 | 26.3 | 42.0 | 67.2 | 82.4 | 0.0 | — |
ADCT — Pillar Breakdown
Quality
— 26.3/100 (25%)ADC Therapeutics S.A. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 67.2/100 (20%)ADC Therapeutics S.A. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 82.4/100 (15%)ADC Therapeutics S.A. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)ADC Therapeutics S.A. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 42/100 (25%)ADC Therapeutics S.A. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ADCT.
Score Composition
Financial Data
More Stock Analysis
How is the ADCT UQS Score Calculated?
The UQS (Unified Quality Score) for ADC Therapeutics S.A. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses ADC Therapeutics S.A.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether ADC Therapeutics S.A. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.